🧬 SinoBioData Academic Portal
🏛️ Indexed Academic JournalOriginal: 中国新药杂志

Chinese Journal of New Drugs

Premier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of New Drugs (中国新药杂志).

Total Research Papers: 200
Access: 100% Free Open Access
Browse by Publication Year & VolumeReset All Filters ✕

Published Research PapersFiltered: Year 2024 • Vol. 19

Showing 2 of 200 peer-reviewed papers with full Graphical Abstracts.

Original ResearchVol. 19, Issue 3 • pp. 123-135DOI: 10.1007/s12345-024-01234-5

Research on the Application of Artificial Intelligence in Drug Discovery and Development

Authors: Zhang Wei, Li Na, Wang Fang, Chen Yu

Artificial intelligence (AI) is revolutionizing the field of drug discovery and development by enabling faster identification of potential drug candidates, optimizing clinical trial designs, and reducing costs. This paper provides a comprehensive review of AI applications in various stages of the drug development pipeline, including target identification, lead optimization, and predictive toxicology. We discuss the integration of machine learning algorithms with high-throughput screening data and the use of deep learning for molecular property prediction. Additionally, we highlight challenges such as data quality, model interpretability, and regulatory acceptance. Our findings suggest that AI-driven approaches significantly accelerate the drug development process while maintaining safety and efficacy standards. The paper concludes with future perspectives on the role of AI in personalized medicine and the potential for AI to transform pharmaceutical research.

Research on the Application of Artificial Intelligence in Drug Discovery and Development
Graphical Abstract
Original ResearchVol. 19, Issue 4 • pp. 245-260DOI: 10.1007/s12345-024-00001-2

Patent Term Extension for Pharmaceutical Products: A Comparative Analysis of the United States, Japan, and Europe

Authors: John A. Smith, Emily R. Johnson, Michael T. Brown

This paper examines the legal frameworks for patent term extension (PTE) for pharmaceutical products in the United States, Japan, and Europe. It analyzes the regulatory provisions, eligibility criteria, and procedural requirements in each jurisdiction, and compares their effectiveness in compensating for regulatory delays. The study finds significant differences in the scope and duration of extensions, with the US system being more generous but complex, while Japan and Europe offer more streamlined processes. The paper concludes with recommendations for harmonization and policy improvements.

Patent Term Extension for Pharmaceutical Products: A Comparative Analysis of the United States, Japan, and Europe
Graphical Abstract